Latest Regulatory Milestones News

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

Findi Limited has secured a perpetual White Label ATM licence from the Reserve Bank of India, removing renewal hurdles and deployment limits. This milestone positions Findi to accelerate its digital financial services expansion across India’s underbanked regions.

Chalice Mining confirms its Gonneville Project Pre-Feasibility Study remains on track for Q4 2025, with environmental approvals progressing smoothly toward a late 2027 Final Investment Decision. The project’s staged open-pit design and innovative infrastructure plans underscore its strategic importance in critical minerals supply.

Astron Corporation has received the Victorian Government's final regulatory green light for its Donald Rare Earths and Mineral Sands Project, paving the way for construction and financing. This milestone advances a strategically vital project aimed at supplying critical minerals for clean energy and defense.

New World Resources has secured a crucial environmental permit for its Antler Copper Project in Arizona, accelerating its path toward construction. This milestone reflects strong state support and positions the company to begin building later in 2025.

Cyprium Metals has obtained crucial environmental and operational approvals to advance the phased redevelopment of its Nifty Copper Complex, setting the stage for a near-term production restart.

Alara Resources reports compelling copper assay results from its Block 8 concession in Oman, with Power Metal Resources advancing its stake and exploration activities moving towards drilling.

Envirosuite has secured a key regulatory green light from FIRB for its acquisition by Ideagen, moving the proposed Scheme of Arrangement closer to shareholder approval.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Sipa Resources has secured key environmental approvals to begin drilling at its newly acquired South Australian gold projects, signaling a major step forward in its exploration plans.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.